Latest filings (excl ownership)
15-12B
Securities registration termination
17 Nov 17
EFFECT
Notice of effectiveness
13 Nov 17
25-NSE
Exchange delisting
7 Nov 17
8-K
Ultragenyx Completes Tender Offer and Acquisition of Dimension Therapeutics
7 Nov 17
POS AM
Prospectus update (post-effective amendment)
7 Nov 17
S-8 POS
Registration of securities for employees (post-effective amendment)
7 Nov 17
S-8 POS
Registration of securities for employees (post-effective amendment)
7 Nov 17
S-8 POS
Registration of securities for employees (post-effective amendment)
7 Nov 17
SC 14D9/A
Tender offer solicitation (amended)
7 Nov 17
SC TO-T/A
Third party tender offer statement (amended)
7 Nov 17
10-Q
2017 Q3
Quarterly report
6 Nov 17
SC 14D9/A
Tender offer solicitation (amended)
27 Oct 17
SC 14D9/A
Tender offer solicitation (amended)
26 Oct 17
SC TO-T/A
Third party tender offer statement (amended)
26 Oct 17
SC 14D9/A
Tender offer solicitation (amended)
23 Oct 17
SC TO-T/A
Third party tender offer statement (amended)
23 Oct 17
SC 14D9/A
Tender offer solicitation (amended)
17 Oct 17
SC TO-T/A
Third party tender offer statement (amended)
17 Oct 17
SC 14D9/A
Tender offer solicitation (amended)
12 Oct 17
SC TO-T/A
Third party tender offer statement (amended)
12 Oct 17
SC 14D9/A
Tender offer solicitation (amended)
11 Oct 17
SC TO-T/A
Third party tender offer statement (amended)
11 Oct 17
SC 14D9
Tender offer solicitation
10 Oct 17
SC TO-T
Third party tender offer statement
10 Oct 17
425
Business combination disclosure
3 Oct 17
8-K
Ultragenyx to Acquire Dimension Therapeutics
3 Oct 17
SC TO-C
Information about tender offer
3 Oct 17
SC14D9C
Written communication relating to third party tender offer
3 Oct 17
SC14D9C
Written communication relating to third party tender offer
3 Oct 17
425
Business combination disclosure
2 Oct 17
8-K
Other Events
2 Oct 17
DEFA14A
Additional proxy soliciting materials
2 Oct 17
DEFA14A
Additional proxy soliciting materials
2 Oct 17
SC TO-C
Information about tender offer
2 Oct 17
SC TO-C
Information about tender offer
25 Sep 17
8-K
Dimension to Begin Discussions with Ultragenyx
19 Sep 17
DEFA14A
Additional proxy soliciting materials
19 Sep 17
DEFA14A
Additional proxy soliciting materials
19 Sep 17
SC TO-C
Information about tender offer
19 Sep 17
8-K
Other Events
18 Sep 17
Latest ownership filings
4
Change in insider ownership
9 Nov 17
4
John Hohneker
7 Nov 17
4
Samuel C. Wadsworth
7 Nov 17
4
Eric Crombez
7 Nov 17
4
GEORGE V MIGAUSKY
7 Nov 17
4
Mary Thistle
7 Nov 17
4
GEORGES GEMAYEL
7 Nov 17
4
Arlene Morris
7 Nov 17
4
Alan Colowick
7 Nov 17
4
Annalisa Jenkins
7 Nov 17
4
Michael Dybbs
7 Nov 17
4
Annalisa Jenkins
5 Jul 17
4
GEORGES GEMAYEL
26 May 17
4
Michael Dybbs
26 May 17
4
Arlene Morris
26 May 17
4
Alan Colowick
26 May 17
4
GEORGE V MIGAUSKY
26 May 17
SC 13G/A
Dimension Therapeutics, Inc.
14 Feb 17
SC 13G/A
Dimension Therapeutics, Inc.
14 Feb 17
4
K. Reed Clark
3 Feb 17
4
Mary Thistle
3 Feb 17
4
Annalisa Jenkins
3 Feb 17
4
Jean M. Franchi
3 Feb 17
4
Samuel C. Wadsworth
3 Feb 17
4
Eric Crombez
3 Feb 17
3
John Hohneker
20 Jan 17
4
John Hohneker
20 Jan 17
4
K. Reed Clark
8 Jun 16
4
Michael Dybbs
23 May 16
4
GEORGE V MIGAUSKY
23 May 16
4
Alan Colowick
23 May 16
4
Arlene Morris
23 May 16
4
GEORGES GEMAYEL
23 May 16
4
Rishi Gupta
23 May 16
SC 13G
Dimension Therapeutics, Inc.
6 May 16
4
Change in insider ownership
3 May 16
SC 13G
Dimension Therapeutics, Inc.
12 Feb 16
4
Eric Crombez
2 Feb 16
4
Annalisa Jenkins
2 Feb 16
4
K. Reed Clark
2 Feb 16